Related references
Note: Only part of the references are listed.Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes
Tania Luthra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and exploration of in silico α-amylase and α-glucosidase binding studies of pyrrolidine-appended quinoline-constrained compounds
P. Hemanth Kumar et al.
RESEARCH ON CHEMICAL INTERMEDIATES (2020)
Design, synthesis, α-amylase inhibition and in silico docking study of novel quinoline bearing proline derivatives
M. S. Ganesan et al.
JOURNAL OF MOLECULAR STRUCTURE (2020)
Synthesis, biological evaluation, molecular docking, molecular dynamics and DFT studies of quinoline-fluoroproline amide hybrids
M.S. Ganesan et al.
JOURNAL OF MOLECULAR STRUCTURE (2020)
Pyrrolidine alkaloids and their promises in pharmacotherapy
Muhammad Torequl Islam et al.
ADVANCES IN TRADITIONAL MEDICINE (2020)
Synthesis and inhibitory activity of N-acetylpyrrolidine derivatives on α-glucosidase and α-amylase
Sompong Sansenya et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2020)
Stereochemical diversity in pyrrolidine synthesis by catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides
Javier Adrio et al.
CHEMICAL COMMUNICATIONS (2019)
Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus
S. O. Kuranov et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents
Rina Soni et al.
BIOORGANIC CHEMISTRY (2018)
Insulin Therapy for Diabetes Epidemic: A Patent Review
Runjhun Tandon et al.
CURRENT DRUG DELIVERY (2018)
Chiral hybrid materials based on pyrrolidine building units to perform asymmetric Michael additions with high stereocontrol
Sebastian Llopis et al.
CATALYSIS SCIENCE & TECHNOLOGY (2018)
Discovery of 3,3-di(indolyl)indolin-2-one as a novel scaffold for α-glucosidase inhibitors: In silico studies and SAR predictions
Guangcheng Wang et al.
BIOORGANIC CHEMISTRY (2017)
Synthesis and α-glucosidase inhibition activity of dihydroxy pyrrolidines
Sivaprasad Kasturi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Bioactivities of a New Pyrrolidine Alkaloid from the Root Barks of Orixa japonica
Xin Chao Liu et al.
MOLECULES (2016)
Design and synthesis of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents
Radhika Sharma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among US FDA Approved Pharmaceuticals
Edon Vitaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes
Jiang Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors
Yang Liu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Synthesis, Evaluation and Molecular Docking of Prolyl-Fluoropyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors
Mani Sharma et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Discovering Novel α-aminoacyl-Containing Proline Derivatives with Potent and Selective Inhibitory Activity Against Dipeptidyl Peptidase IV: Design, Synthesis, Biological Evaluation, and Molecular Modeling
Xiaodong Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives
Lei Chen et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Incretin-based therapies
Anthony H. Stonehouse et al.
JOURNAL OF DIABETES (2012)
Management of diabetes mellitus in the elderly
Niyati Chiniwala et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2011)
Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Nasser Mikhail
CURRENT DRUG DELIVERY (2011)
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial
Julio Rosenstock et al.
LANCET (2010)
Synthesis and Evaluation of Novel Compounds as Potent Dipeptidyl Peptidase IV Inhibitors
Liutang Wang et al.
SYNTHETIC COMMUNICATIONS (2010)
Cost-effectiveness of insulin analogues for diabetes mellitus
Chris G. Cameron et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
EPIBATIDINE ANALOGS SYNTHESIZED FOR CHARACTERIZATION OF NICOTINIC PHARMACOPHORES-A REVIEW
F. Ivy Carroll
HETEROCYCLES (2009)
Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
Hiroshi Fukushima et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
Hiroshi Fukushima et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2008)
Diabetes in Sub-Saharan Africa: Kenya, Mali, Mozambique, Nigeria, South Africa and Zambia
Mario Azevedo et al.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES (2008)
Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP
Yong Deuk Kim et al.
DIABETES (2008)
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
A. Barnett
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle
Cheryl A. Collier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Meglitinide analogues:: a review of clinical data focused on recent trials
JF Blicklé
DIABETES & METABOLISM (2006)
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
DJ Augeri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Where are the reversible dementias?
R Harisingani
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
In the golden age of organocatalysis
PI Dalko et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability:: Interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors
DR Magnin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
1-[2-[(5-cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-(S)-pyrrolidine-carbonitrile:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
FB Hu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
